These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33996732)

  • 1. Do Regulatory Changes Seriously Affect the Medical Devices Industry? Evidence From the Czech Republic.
    Maresova P; Rezny L; Peter L; Hajek L; Lefley F
    Front Public Health; 2021; 9():666453. PubMed ID: 33996732
    [No Abstract]   [Full Text] [Related]  

  • 2. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engaging with economic evaluation methods: insights from small and medium enterprises in the UK medical devices industry after training workshops.
    Craven MP; Allsop MJ; Morgan SP; Martin JL
    Health Res Policy Syst; 2012 Sep; 10():29. PubMed ID: 22943625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H; Shibatsuji M; Yasuda N
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
    Vostalová L; Mazelová J; Samek J; Vocelka M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.
    Hwang TJ; Sokolov E; Franklin JM; Kesselheim AS
    BMJ; 2016 Jun; 353():i3323. PubMed ID: 27352914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical device regulation for manufacturers.
    McAllister P; Jeswiet J
    Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Information society in Czech healthcare 'starting point' to prognosis for the year 2013.
    Zvárová J; Pribík V
    Int J Med Inform; 2002 Nov; 66(1-3):59-68. PubMed ID: 12453559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Industry regulation and its relationship to the rapid marketing of medical devices].
    Matsuoka A
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):13-20. PubMed ID: 23243983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First results of participation of the Czech Republic in the 7th Framework Programme, priority Health, in years 2007-2013].
    Kinkorová J
    Cas Lek Cesk; 2013; 152(4):206-10. PubMed ID: 24041023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic burden of the care and treatment for people with Alzheimer's disease: the outlook for the Czech Republic.
    Marešová P; Zahálková V
    Neurol Sci; 2016 Dec; 37(12):1917-1922. PubMed ID: 27470305
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.